- Trial phase
- Approved (FDA approval 2019-11-20)
- Time to market
- Already approved and on the market, FDA approval recorded 2019-11-20; no new regulatory decision pending.
- Why 3/10
- GIVLAARI was FDA-approved on 2019-11-20 and has no PDUFA, pivotal readout or other hard dated regulatory binary scheduled in the next ~12 months, it is an approved, commercialized product and only one of several marketed drugs at Alnylam, so it scores 3 per the approved-drug-no-binary rule.
Watch Alnylam's quarterly earnings for the TTR-franchise trajectory and total product revenue, since GIVLAARI's own newsflow is minimal now that it is approved, do not expect a Givlaari-specific binary in the next 12 months. For a trade on ALNY itself, the near-term drivers are the ATTR-CM (vutrisiran/patisiran) commercial ramp and the Regeneron cemdisiran NDA (filed 2026-04-30), not this drug. Re-verify the drug's label/mechanism and any competitive or pricing news with live web sources, since DuckDuckGo was unavailable during this session.
Price Chart
Executive Summary
GIVLAARI (givosiran) is Alnylam's RNAi therapy for acute hepatic porphyria, approved by the FDA on 2019-11-20 per SecBot's catalyst/outcome records (the stock moved +13.55% the day of and +14.8% over five days around that approval). It is an established commercial product in an ultra-rare disease, so it is a steady but small contributor to Alnylam (ALNY, Nasdaq, confirmed via SEC-derived index), whose value now rests mainly on the larger TTR-amyloidosis franchise.
How It Works
GIVLAARI is a small interfering RNA (RNAi) medicine, a short piece of synthetic genetic material injected under the skin once a month that travels to liver cells and "silences" a specific gene (ALAS1). That gene makes an enzyme that drives the buildup of toxic heme-building chemicals; in people with acute hepatic porphyria those chemicals trigger severe, sometimes dangerous abdominal/neurological attacks. By turning down ALAS1, GIVLAARI reduces attack-driving toxins at their source.
Trial Status
Approved and commercialized for acute hepatic porphyria (AHP); no givosiran Phase 2/3 trial records appear in SecBot's local ClinicalTrials.gov ingestion window, and no upcoming regulatory catalyst for this drug is on record, the only ALNY FDA catalyst in the past year is Regeneron's cemdisiran NDA (2026-04-30), a different molecule.
The Two-Sided Case
Upcoming Catalysts
- No hard dated catalyst for GIVLAARI itself (approved, no pending PDUFA/readout).
- Alnylam quarterly earnings (next after the 2026-07-30 Q2 release), total product revenue and TTR guidance updates.
- Regeneron/Alnylam cemdisiran NDA (gMG) review milestones, a different molecule but an ALNY-relevant regulatory event.
- Continued commercial ramp and any payer/formulary developments for the approved portfolio.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report